$CARM

Carisma Therapeutics Inc.

No enriched coverage for $CARM in the last 7 days.

No SEC Form 4 filings for $CARM in the last 30 days.

CARM sentiment & insider activity

What's driving CARM

  • The positive market sentiment and Dow's surge suggest a cautiously optimistic environment for biotech stocks like CARM.

    Benzinga · Oct 10, 2025

  • CARM shows a somewhat bullish sentiment, indicating potential for short-term gains if positive news or catalysts emerge.

    Benzinga · Sep 2, 2025

  • Carisma Therapeutics (CARM) experienced a somewhat bullish sentiment, indicating investor optimism possibly driven by sector developments or company-specific news.

    Benzinga · Sep 2, 2025

  • The investigation by class action attorney Juan Monteverde into Carisma Therapeutics' merger introduces legal uncertainty, potentially affecting stock price and investor confidence.

    Benzinga · Jun 30, 2025

  • CARM shows neutral sentiment with limited impact from the investigation news.

    Benzinga · Jun 27, 2025

alphai scores every news story that mentions CARM with an AI model for sentiment and relevance, and aggregates insider trades from Carisma Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CARM

Score
$CARMMed

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)

BALA CYNWYD, Pa., June 27, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.